Equity Overview
Price & Market Data
Price: $9.12
Daily Change: -$0.0₄1 / 0.00%
Range: $8.88 - $9.23
Market Cap: $832,434,304
Volume: 5,212
Performance Metrics
1 Week: 14.86%
1 Month: -3.90%
3 Months: -13.96%
6 Months: -35.55%
1 Year: -42.86%
YTD: -24.63%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.